«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:

期数:

2017年02期

页码:

150-153

栏目:

论著

出版日期:

2017-03-27

文章信息/Info

Title:

Influence and curative effect observation of montelukast and pidotimod on cellular immune function and pulmonary function of children with cough variant asthma

作者:

扈雯雯¹; 赵家艳²

1. 威海市中心医院儿科，山东威海264400 2. 新乡医学院第三附属医院儿科，河南新乡453000

Author(s):

HU Wen-wen*; ZHAO Jia-yan

*Department of Pediatrics, Weihai Central Hospital,Weihai, Shandong 264400, China Corresponding author: HU Wen-wen, E-mail: zjyxinxiang@sina.com

关键词:

匹多莫德; 孟鲁司特; 咳嗽变异性哮喘; 细胞免疫功能; 肺功能

Keywords:

Montelukast;  Pidotimod;  Cough variant asthma;  Cellular immune function;  Pulmonary function

分类号:

R725.6

DOI:

-

摘要:

目的探讨匹多莫德联合孟鲁司特治疗小儿咳嗽变异性哮喘（CVA） 的临床疗效及对细胞免疫和肺功 能的影响。方法选取2014 年6 月—2015 年9 月威海市中心医院收治的72 例CVA 儿童，随机分为对照组和观 察组，各36例。对照组给予单纯口服孟鲁司特治疗，观察组在对照组治疗的基础上给予口服匹多莫德治疗，两组 均连续治疗3 个月，治疗后随访3 个月。观察两组的临床疗效及随访情况，并比较两组患儿治疗前后细胞免疫功 能和肺功能的改善情况。结果观察组患儿临床治疗总有效率为94.44%，明显高于对照组的83.33%，差异有 统计学意义（P＜0.05）；治疗3 个月后，观察组患者CD4 +、CD8 +水平和CD4 +/CD8 +比值分别为（42.85 ± 4.93） %、（23.71±2.96） %、（1.80±0.27），与对照组比较差异有统计意义（P＜0.05）；观察组患儿咳嗽症状评分 为（2.07±0.24） 分，明显低于对照组；观察组患儿第1 秒用力呼气量和峰值呼气流速分别为（3.95±0.38） L， （6.18±0.73） L/s，明显高于对照组，差异有统计学意义（P＜0.05）；观察组患儿随访期内哮喘平均发作次数、 发作持续时间及呼吸道感染发生次数均明显低于对照组（P＜0.05）。结论匹多莫德联合孟鲁司特治疗小儿 CVA 的疗效确切，能够有效改善患儿的细胞免疫功能和肺功能。

Abstract:

Objective To investigate influence and curative effect observation of montelukast and pidotimod on cellular immune function and pulmonary function of children with cough variant asthma. Methods A total of 72 children with cough variant asthma from September 2015 to June 2014 was randomly divided into control group (36 cases) and combined group (36 cases). The control group was treated with montelukast, and the combination group was were treated with pidotimod on the basis of the control group. The clinical curative effect and follow-up survey of two groups were observed, and the cellular immune function and pulmonary function before and after treatment between the two groups were compared. Results The total effective rate of the combined group (94.44% ) was significantly higher than that of the control group (83.33% , P＜0.05); After 3 months of treatment, the CD4 + , CD8+ levels andCD4+/CD8+ ratio of combined group were (42.85±4.93)%, (23.71±2.96)% and (1.80± 0.27), and the differences were statistically significant between the two groups (P<0.05). The cough symptom score of combined group was (2.07 ± 0.24) points which was significantly lower than that ofthe control group (P＜0.05). The forced expiratory volume in 1s and peak expiratory flow rate of combined group were (3.95±0.38) L and (6.18±0.73) L/s which were significantly higher than those of the control group (P＜0.05). The average number of asthma attacks and respiratory infections, duration of attack of combined group during follow- up period were significantly lower than those of the control group (P＜0.05). Conclusion Montelukast combined with pidotimod has reliable curative effect on children with cough variant asthma by improving cellular immune function and pulmonary function.

参考文献/References:

[1] 张永明,林江涛.咳嗽变异性哮喘诊断和治疗新认识[J].中华结核 和呼吸杂志,2012,35(1):62-64.
[2] 薛满,马春利,梁宽,等. 孟鲁司特钠治疗小儿咳嗽变异性哮喘的 临床疗效及安全性研究[J]现代生物医学进展,2012,12(17): 3317-3319
[3] 陈潮青,罗学虹,陈宜升,等. 匹多莫德联合孟鲁司特治疗小儿反 复发作性哮喘的疗效观察[J]. 中华全科医学,2013,11(8):1204- 1205.
[4] 吴艳玲,张海邻. 儿童咳嗽变异性哮喘诊治进展[J]. 中华儿科杂 志,2016,54(4):314-317.
[5] 陈晓磊.孟鲁司特钠治疗小儿咳嗽变异性哮喘的效果与安全性分 析[J].河南医学研究,2016,25(5):930-931.
[6] 陈斌华. 孟鲁司特钠联合布地奈德治疗儿童咳嗽变异性哮喘的 临床疗效和安全性[J]. 国际医药卫生导报,2013,19(9):1292- 1294.
[7] 秦蔚,赵宇华. 布地奈德联合孟鲁司特对小儿咳嗽变异性哮喘血 清白介素-8、肿瘤坏死因子-α 及转化生长因子β1 水平的影响 [J].中国医药导报,2013,10(35):95-97.
[8] 张蕾,王风圈. 匹多莫德口服液辅助治疗儿童反复呼吸道感染临 床疗效观察[J].中国现代药物应用,2010,4(19):151-152.
[9] 吉朝利,刘小红. 匹多莫德联合孟鲁司特对支气管哮喘患儿的疗 效及肺功能影响的临床研究[J]. 湖北科技学院学报( 医学版), 2016,30(2):116-118.
[10] 王春燕.匹多莫德联合孟鲁司特对咳嗽变异性哮喘患儿细胞免疫 功能的影响及疗效观察[J].中国医药导报,2015,12(2):82-85.

备注/Memo

备注/Memo:

作者简介：扈雯雯，本科，主治医师，研究方向：儿科临床 通信作者：扈雯雯，E-mail：zjyxinxiang@sina.com

常用功能

更新日期/Last Update: 2017-02-18